# IDRX-42-001 (NCT05489237)

> First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05489237
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC
- Conditions: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease; Gastrointestinal Diseases; Metastatic Cancer
- Interventions: IDRX-42
- Enrollment: 276
- Primary outcome: Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)
- Primary outcome: Phase 1 (Dose Escalation) - Safety and Tolerability (Nature, incidence, and severity of any DLTs)
- Primary outcome: Phase 1 (Dose Escalation) - Determination of the MTD and/or RP1bD(s) of orally administered IDRX-42
- Primary outcome: Phase 1 (Dose Escalation) - C-QTc sub-study: QTcF - concentration response analysis
- Primary outcome: Phase 1b-Number of participants with TEAEs and with laboratory test results
- Primary outcome: Phase 1b - Objective Response Rate (ORR) mRESIST v1.1
- Primary outcome: Phase 1b - C-QTcF sub-study: QTcF - concentration response analysis

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 6
- YouTube: 1
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=idrx-42-001-nct05489237

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05489237", "email": "<work email>"}; the inbox owner confirms by the emailed link.